It is tempting to speculate that the utility of mTOR inhibitors in a number of age-related diseases (reviewed in [48]) including Alzheimer's disease ([49]; reviewed in [50]) and immune senescence [51], as well as their ability to improve ageing human skin structure [52], may be at least in part through actin cytoskeletal modulation that impacts TNT formation. This evidence concerns the gene MTOR and early-onset autosomal dominant Alzheimer disease.